Nephro-Urology Monthly

Published by: Kowsar

Antiproliferative and Antioxidant Effects of Withania coagulans Extract on Benign Prostatic Hyperplasia in Rats

Maryam Sarbishegi 1 , * , Mohaddeseh Khani 1 , Saeedeh Salimi 2 , Mohharam Valizadeh 3 and Fereydoon Sargolzaei Aval 1
Authors Information
1 Department of Anatomy, School of Medicine, Zahedan University of Medical Sciences, Zahedan, IR Iran
2 Cellular and Molecular Research Center, Zahedan University of Medical Sciences, Zahedan, IR Iran
3 Department of Medicinal and Aromatic Plant, High Complex Education of Saravan, Saravan, IR Iran
Article information
  • Nephro-Urology Monthly: January 01, 2016, 8 (1); e33180
  • Published Online: January 9, 2016
  • Article Type: Research Article
  • Received: September 15, 2015
  • Accepted: November 7, 2015
  • DOI: 10.5812/numonthly.33180

To Cite: Sarbishegi M, Khani M, Salimi S, Valizadeh M, Sargolzaei Aval F. Antiproliferative and Antioxidant Effects of Withania coagulans Extract on Benign Prostatic Hyperplasia in Rats, Nephro-Urol Mon. 2016 ; 8(1):e33180. doi: 10.5812/numonthly.33180.

Abstract
Copyright © 2016, Nephrology and Urology Research Center. This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/) which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited.
1. Background
2. Objectives
3. Materials and Methods
4. Results
5. Discussion
Acknowledgements
Footnotes
References
  • 1. Shin IS, Lee MY, Ha HK, Seo CS, Shin HK. Inhibitory effect of Yukmijihwang-tang, a traditional herbal formula against testosterone-induced benign prostatic hyperplasia in rats. BMC Complement Altern Med. 2012; 12: 48[DOI][PubMed]
  • 2. Roehrborn CG. Male lower urinary tract symptoms (LUTS) and benign prostatic hyperplasia (BPH). Med Clin North Am. 2011; 95(1): 87-100[DOI][PubMed]
  • 3. Barkin J. Benign prostatic hyperplasia and lower urinary tract symptoms: evidence and approaches for best case management. Can J Urol. 2011; 18 Suppl: 14-9[PubMed]
  • 4. McVary KT. A review of combination therapy in patients with benign prostatic hyperplasia. Clin Ther. 2007; 29(3): 387-98[PubMed]
  • 5. Roehrborn CG, Rosen RC. Medical therapy options for aging men with benign prostatic hyperplasia: focus on alfuzosin 10 mg once daily. Clin Interv Aging. 2008; 3(3): 511-24[PubMed]
  • 6. Gravas S, Oelke M. Current status of 5alpha-reductase inhibitors in the management of lower urinary tract symptoms and BPH. World J Urol. 2010; 28(1): 9-15[DOI][PubMed]
  • 7. Bullock TL, Andriole Jr GL. Emerging drug therapies for benign prostatic hyperplasia. Expert Opin Emerg Drugs. 2006; 11(1): 111-23[DOI][PubMed]
  • 8. Gerber GS. Phytotherapy for benign prostatic hyperplasia. Curr Urol Rep. 2002; 3(4): 285-91[PubMed]
  • 9. Beigomi M, Mohammadifar MA, Hashemi M, rohani MG, Senthil K, Valizadeh M. Biochemical and rheological characterization of a protease from fruits of Withania coagulans with a milk-clotting activity. Food Sci Biotechnol. 2014; 23(6): 1805-13[DOI]
  • 10. Gupta P. Withania coagulans Dunal-An Overview. Int J Pharmaceut. 2012; 12(2): 68-71
  • 11. Khodaei M, Jafari M, Noori M. Remedial Use of Withanolides from Withania Coagolans (Stocks) Dunal. Adv Life Sci. 2012; 2(1): 6-19[DOI]
  • 12. Ye L, Kynaston H, Jiang WG. Bone morphogenetic protein-9 induces apoptosis in prostate cancer cells, the role of prostate apoptosis response-4. Mol Cancer Res. 2008; 6(10): 1594-606[DOI][PubMed]
  • 13. Srinivasan S, Ranga RS, Burikhanov R, Han SS, Chendil D. Par-4-dependent apoptosis by the dietary compound withaferin A in prostate cancer cells. Cancer Res. 2007; 67(1): 246-53[DOI][PubMed]
  • 14. Nahata A, Dixit VK. Ameliorative effects of stinging nettle (Urtica dioica) on testosterone-induced prostatic hyperplasia in rats. Andrologia. 2012; 44 Suppl 1: 396-409[DOI][PubMed]
  • 15. Bradford MM. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem. 1976; 72(1-2): 248-54[DOI]
  • 16. Ohkawa H, Ohishi N, Yagi K. Assay for lipid peroxides in animal tissues by thiobarbituric acid reaction. Anal Biochem. 1979; 95(2): 351-8[DOI]
  • 17. Benzie IF, Strain JJ. The ferric reducing ability of plasma (FRAP) as a measure of "antioxidant power": the FRAP assay. Anal Biochem. 1996; 239(1): 70-6[DOI][PubMed]
  • 18. Lai MD, Lee LR, Cheng KS, Wing LY. Expression of proliferating cell nuclear antigen in luminal epithelium during the growth and regression of rat uterus. J Endocrinol. 2000; 166(1): 87-93[PubMed]
  • 19. Atawia RT, Tadros MG, Khalifa AE, Mosli HA, Abdel-Naim AB. Role of the phytoestrogenic, pro-apoptotic and anti-oxidative properties of silymarin in inhibiting experimental benign prostatic hyperplasia in rats. Toxicol Lett. 2013; 219(2): 160-9[DOI][PubMed]
  • 20. Bostanci Y, Kazzazi A, Momtahen S, Laze J, Djavan B. Correlation between benign prostatic hyperplasia and inflammation. Curr Opin Urol. 2013; 23(1): 5-10[DOI][PubMed]
  • 21. Kullisaar T, Turk S, Punab M, Mandar R. Oxidative stress--cause or consequence of male genital tract disorders? Prostate. 2012; 72(9): 977-83[DOI][PubMed]
  • 22. Merendino RA, Salvo F, Saija A, Di Pasquale G, Tomaino A, Minciullo PL, et al. Malondialdehyde in benign prostate hypertrophy: a useful marker? Mediators Inflamm. 2003; 12(2): 127-8[DOI][PubMed]
  • 23. Ahmad M, Suhail N, Mansoor T, Banu N, Ahmad S. Evaluation of oxidative stress and DNA damage in benign prostatic hyperplasia patients and comparison with controls. Indian J Clin Biochem. 2012; 27(4): 385-8[DOI][PubMed]
  • 24. Pace G, Di Massimo C, De Amicis D, Corbacelli C, Di Renzo L, Vicentini C, et al. Oxidative stress in benign prostatic hyperplasia and prostate cancer. Urol Int. 2010; 85(3): 328-33[DOI][PubMed]
  • 25. Salwaan C, Singh A, Mittal A, Singh P. Investigation of the Pharmacognostical, Phytochemical and Antioxidant Studies of Plant Withania Coagulans Dunal. J Pharmacog Phytochem. 2012; 1: 36-44
  • 26. Hemalatha S, Wahi AK, Singh PN, Chansouria JP. Hypolipidemic activity of aqueous extract of Withania coagulans Dunal in albino rats. Phytother Res. 2006; 20(7): 614-7[DOI][PubMed]
  • 27. Rajasankar S, Manivasagam T, Surendran S. Ashwagandha leaf extract: a potential agent in treating oxidative damage and physiological abnormalities seen in a mouse model of Parkinson's disease. Neurosci Lett. 2009; 454(1): 11-5[DOI][PubMed]
  • 28. Sciarra A, Mariotti G, Salciccia S, Autran Gomez A, Monti S, Toscano V, et al. Prostate growth and inflammation. J Steroid Biochem Mol Biol. 2008; 108(3-5): 254-60[DOI][PubMed]
  • 29. Veeresh Babu SV, Veeresh B, Patil AA, Warke YB. Lauric acid and myristic acid prevent testosterone induced prostatic hyperplasia in rats. Eur J Pharmacol. 2010; 626(2-3): 262-5[DOI][PubMed]
  • 30. Oh JH, Lee TJ, Kim SH, Choi YH, Lee SH, Lee JM, et al. Induction of apoptosis by withaferin A in human leukemia U937 cells through down-regulation of Akt phosphorylation. Apoptosis. 2008; 13(12): 1494-504[DOI][PubMed]
  • 31. Aydin A, Arsova-Sarafinovska Z, Sayal A, Eken A, Erdem O, Erten K, et al. Oxidative stress and antioxidant status in non-metastatic prostate cancer and benign prostatic hyperplasia. Clin Biochem. 2006; 39(2): 176-9[DOI][PubMed]
  • 32. Kyprianou N, Tu H, Jacobs SC. Apoptotic versus proliferative activities in human benign prostatic hyperplasia. Hum Pathol. 1996; 27(7): 668-75[PubMed]
  • 33. Stan SD, Hahm ER, Warin R, Singh SV. Withaferin A causes FOXO3a- and Bim-dependent apoptosis and inhibits growth of human breast cancer cells in vivo. Cancer Res. 2008; 68(18): 7661-9[DOI][PubMed]
  • 34. Ichikawa H, Takada Y, Shishodia S, Jayaprakasam B, Nair MG, Aggarwal BB. Withanolides potentiate apoptosis, inhibit invasion, and abolish osteoclastogenesis through suppression of nuclear factor-kappaB (NF-kappaB) activation and NF-kappaB-regulated gene expression. Mol Cancer Ther. 2006; 5(6): 1434-45[DOI][PubMed]
  • 35. Choudhary MI, Yousuf S. Withanolides: Chemistry and Antitumor Activity. 2013; : 3465-95
  • 36. Huo JX, Metz SA, Li GD. p53-independent induction of p21(waf1/cip1) contributes to the activation of caspases in GTP-depletion-induced apoptosis of insulin-secreting cells. Cell Death Differ. 2004; 11(1): 99-109[DOI][PubMed]
  • 37. Waga S, Hannon GJ, Beach D, Stillman B. The p21 inhibitor of cyclin-dependent kinases controls DNA replication by interaction with PCNA. Nature. 1994; 369(6481): 574-8[DOI][PubMed]
Creative Commons License Except where otherwise noted, this work is licensed under Creative Commons Attribution Non Commercial 4.0 International License .

Search Relations:

Author(s):

Article(s):

Create Citiation Alert
via Google Reader

Readers' Comments